Patents Assigned to Viron Therapeutics, Inc.
-
Publication number: 20120270793Abstract: Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed.Type: ApplicationFiled: October 21, 2010Publication date: October 25, 2012Applicant: Viron Therapeutics Inc.Inventor: Alexandra R. Lucas
-
Patent number: 8268331Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: GrantFiled: May 7, 2009Date of Patent: September 18, 2012Assignee: Viron Therapeutics, Inc.Inventors: Grant McFadden, Karim Essani
-
Patent number: 8227569Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.Type: GrantFiled: March 2, 2010Date of Patent: July 24, 2012Assignee: Viron Therapeutics Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Publication number: 20110064757Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: ApplicationFiled: May 7, 2009Publication date: March 17, 2011Applicant: Viron Therapeutics, Inc.Inventors: Grant McFadden, Karim Essani
-
Patent number: 7906483Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.Type: GrantFiled: February 23, 2009Date of Patent: March 15, 2011Assignee: Viron Therapeutics Inc.Inventors: Alexandra Lucas, Z. Robert Zhong, D. Grant McFadden
-
Publication number: 20100331524Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.Type: ApplicationFiled: March 2, 2010Publication date: December 30, 2010Applicant: Viron Therapeutics Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Patent number: 7745396Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.Type: GrantFiled: September 7, 2007Date of Patent: June 29, 2010Assignee: Viron Therapeutics Inc.Inventor: Alexandra Lucas
-
Patent number: 7718368Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.Type: GrantFiled: August 17, 2006Date of Patent: May 18, 2010Assignee: Viron Therapeutics Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Patent number: 7585507Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: GrantFiled: May 9, 2005Date of Patent: September 8, 2009Assignee: Viron Therapeutics Inc.Inventors: Grant McFadden, Karim Essani
-
Patent number: 7514405Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.Type: GrantFiled: March 13, 2003Date of Patent: April 7, 2009Assignee: Viron Therapeutics Inc.Inventors: Alexandra Lucas, Robert Zhong, D. Grant McFadden
-
Publication number: 20090011979Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.Type: ApplicationFiled: August 17, 2006Publication date: January 8, 2009Applicant: Viron Therapeutics, Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Patent number: 7419670Abstract: Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1/immunosuppressant combination admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.Type: GrantFiled: September 28, 2001Date of Patent: September 2, 2008Assignee: Viron Therapeutics, Inc.Inventors: Robert Z. Zhong, Alexandra Lucas, Grant D. McFadden
-
Publication number: 20080070841Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.Type: ApplicationFiled: September 7, 2007Publication date: March 20, 2008Applicant: Viron Therapeutics, Inc.Inventor: Alxandria Lucas
-
Patent number: 7285530Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.Type: GrantFiled: October 21, 2005Date of Patent: October 23, 2007Assignee: Viron Therapeutics, Inc.Inventor: Alexandra Lucas
-
Publication number: 20060286125Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: ApplicationFiled: May 9, 2005Publication date: December 21, 2006Applicant: Viron Therapeutics, Inc.Inventors: Grant McFadden, Karim Essani
-
Patent number: 7101559Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immune-related diseases.Type: GrantFiled: June 4, 2003Date of Patent: September 5, 2006Assignee: Viron Therapeutics, Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Publication number: 20030171263Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.Type: ApplicationFiled: March 13, 2003Publication date: September 11, 2003Applicant: Viron Therapeutics, Inc.Inventors: Alexandra Lucas, Robert Zhong, D. Grant McFadden
-
Patent number: 6589933Abstract: The present invention provides a method of use for a novel chemokine binding protein 5(type-2 CBP) encoded by poxviruses and having amino acid sequence homology with the Shope fibroma virus T1 family of proteins against disease syndromes associated with acute or chronic dysregulated inflammatory responses.Type: GrantFiled: September 15, 1999Date of Patent: July 8, 2003Assignee: Viron Therapeutics, Inc.Inventors: Grant McFadden, Alexandra Lucas
-
Patent number: 6495515Abstract: The present invention provides a method of use for a novel type I chemokine binding protein encoded by poxviruses and having amino acid sequence homology with the myxoma virus T7 interferon-&ggr; receptor homolog against disease syndromes associated with acute or chronic dysregulated inflammatory responses.Type: GrantFiled: September 14, 1999Date of Patent: December 17, 2002Assignee: Viron Therapeutics, Inc.Inventors: Grant McFadden, Alexandra Lucas
-
Patent number: 5939525Abstract: Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1, SERP-1 analog or biologically active fragment thereof admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. Biologically active SERP-1 analogs are also provided. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.Type: GrantFiled: March 27, 1995Date of Patent: August 17, 1999Assignee: Viron Therapeutics, Inc.Inventors: D. Grant McFadden, Alexandra Lucas